List of Excipients in Branded Drug 7 SELECT ANTI DIARRHEAL

Generic Drugs Containing 7 SELECT ANTI DIARRHEAL

Company	Ingredient	NDC	Excipient
7-Eleven	loperamide hcl	10202-224	ANHYDROUS LACTOSE
7-Eleven	loperamide hcl	10202-224	CARNAUBA WAX
7-Eleven	loperamide hcl	10202-224	CELLULOSE, MICROCRYSTALLINE
7-Eleven	loperamide hcl	10202-224	D&C YELLOW NO. 10
7-Eleven	loperamide hcl	10202-224	FD&C BLUE NO. 1
7-Eleven	loperamide hcl	10202-224	HYPROMELLOSES

What are the Most Frequently-Used Excipients in 7 SELECT ANTI DIARRHEAL?

# Of NDCs	Excipient
1	ANHYDROUS CITRIC ACID
1	ANHYDROUS LACTOSE
1	CARBOXYMETHYLCELLULOSE SODIUM
1	CARNAUBA WAX
2	CELLULOSE, MICROCRYSTALLINE
2	D&C YELLOW NO. 10

7 Select Anti-Diarrheal Excipient Strategy and Commercial Opportunities

Last updated: September 5, 2026

7 Select Anti-Diarrheal is a private-label OTC loperamide hydrochloride product sold through Walmart. Its commercial position depends less on molecule-level patent protection than on low-cost manufacturing, FDA monograph compliance, shelf stability, packaging, and differentiation through dosage form and excipient selection. The core opportunity is to improve manufacturability and consumer experience without changing the approved active ingredient strength or creating avoidable regulatory risk.

What active ingredient and dosage form does 7 Select Anti-Diarrheal use?

7 Select Anti-Diarrheal is labeled as loperamide hydrochloride 2 mg per dosage unit, the same active ingredient and strength used in leading branded and generic antidiarrheal products. Loperamide is an opioid-receptor agonist that acts primarily in the gastrointestinal tract and is marketed for symptomatic control of acute nonspecific diarrhea.

The product is generally positioned as an immediate-release oral solid dosage form. The applicable commercial reference is the OTC loperamide category rather than a newly approved prescription drug.

Product characteristic	Commercial position
Brand	7 Select
Retailer	Walmart
Active ingredient	Loperamide hydrochloride
Typical strength	2 mg per caplet or tablet
Therapeutic category	OTC antidiarrheal
Primary indication	Symptomatic relief of diarrhea
Distribution model	Private-label retail
Regulatory pathway	OTC monograph or monograph-compliant labeling
Primary differentiation	Price, packaging, availability, dosage-form execution
Principal IP risk	Low molecule-level risk; moderate formulation and manufacturing risk

FDA-approved labeling for loperamide products generally limits daily use and duration. The product is not intended for children under two years of age, and consumers are directed to seek medical advice for prolonged symptoms, fever, bloody stool, or other warning signs. Those label controls restrict some pediatric and high-dose product concepts. (U.S. Food and Drug Administration [FDA], 2023a)

What excipients are used in 7 Select Anti-Diarrheal?

Public product labeling identifies standard tablet excipients for loperamide immediate-release products. Depending on the specific package and contract manufacturer, the formulation may include microcrystalline cellulose, dibasic calcium phosphate, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, stearic acid, and colorants.

The excipient system is typical of a compressed immediate-release tablet:

Excipient class	Likely function	Commercial relevance
Microcrystalline cellulose	Filler and dry binder	Supports direct compression and tablet robustness
Dibasic calcium phosphate	Filler and compression aid	Low-cost bulk excipient with good flow
Croscarmellose sodium	Superdisintegrant	Promotes rapid tablet breakup
Colloidal silicon dioxide	Glidant	Improves powder flow and die filling
Magnesium stearate	Lubricant	Reduces sticking and ejection force
Stearic acid	Lubricant or structural aid	May support compression and tablet finish
Colorant	Product identification	Supports brand differentiation and compliance
Film-coating materials, if used	Protection and appearance	Improve handling, swallowability, and visual identity

The key design target is rapid disintegration without excessive lubricant interference. Loperamide hydrochloride is used at a low dose relative to the tablet mass. Most excipient risk therefore comes from blend uniformity, segregation, lubrication, tablet hardness, and dissolution control rather than from high drug loading.

How should an excipient strategy be optimized for loperamide tablets?

A cost-efficient formulation should use a robust direct-compression platform unless the selected supplier or manufacturing site requires wet granulation. Direct compression reduces processing steps, lowers energy use, and limits exposure to water and heat.

Immediate-release tablet strategy

A practical formulation architecture includes:

1. A high-functionality filler-binder, such as microcrystalline cellulose.
2. A mineral filler, such as dibasic calcium phosphate, for density and compression.
3. A superdisintegrant positioned to offset tablet hardness.
4. A low-concentration glidant to improve flow.
5. A controlled lubricant addition and blending time.
6. A thin film coat, if needed for appearance, taste masking, or handling.

The principal development variables are:

• Tablet weight and dimensions
• Loperamide blend uniformity
• Compression force
• Tablet tensile strength
• Friability
• Disintegration time
• Dissolution profile
• Lubricant concentration and mixing time
• Moisture exposure
• Coating weight gain
• Packaging protection

Loperamide products should be designed to meet immediate-release dissolution expectations while avoiding an excessively hard tablet. Over-lubrication can slow wetting and dissolution. Excessive calcium phosphate or high compression force can also reduce disintegration unless the superdisintegrant system is balanced.

What formulation patents could protect a 7 Select Anti-Diarrheal line?

The original loperamide composition and basic tablet concept have limited exclusivity value because loperamide hydrochloride is an established active ingredient. Commercially relevant protection would instead focus on formulation and manufacturing features.

Potential claim categories include:

Patent category	Potential protected subject matter	Relative commercial value
Immediate-release composition	Defined excipient ratios and dissolution profile	Low to moderate
Taste-masked formulation	Coated particles, ion-exchange systems, or flavor systems	Moderate
Orally disintegrating tablet	Porous matrix and rapid disintegration	Moderate
Liquid formulation	Solubilizer, suspending agent, preservative, and flavor system	Moderate
Sachet or powder	Dry blend, reconstitution behavior, and moisture control	Moderate
Bilayer or combination tablet	Loperamide with another antidiarrheal component	Moderate to high, but greater regulatory risk
Manufacturing process	Granulation, lubrication, compression, or coating process	Moderate
Packaging system	Moisture barrier, unit-dose format, child-resistant design	Low to moderate
Pediatric delivery system	Dose metering and age-specific administration	Commercially significant, but label constrained

A patent based only on conventional excipients in routine proportions would face substantial validity and obviousness risk. Stronger claims would require a demonstrated technical effect, such as a defined dissolution advantage, improved stability under accelerated conditions, reduced tablet weight, improved taste masking, or a measurable manufacturing benefit.

What is the FDA regulatory status of 7 Select Anti-Diarrheal?

Loperamide hydrochloride is regulated as an OTC antidiarrheal active ingredient under FDA’s OTC framework. A compliant product must meet the applicable monograph conditions, including active ingredient, dosage, directions, warnings, labeling, and quality requirements. The product may also be marketed under an FDA-approved application if the manufacturer has chosen that route.

The regulatory distinction is important:

• A monograph-compliant OTC product does not depend on a conventional new-drug approval for every private-label SKU.
• A materially novel dosage form, indication, strength, combination, or delivery system may fall outside the monograph.
• An excipient change that affects safety, identity, strength, quality, purity, or stability may require regulatory assessment even if the active ingredient and dose remain unchanged.
• A new combination product may trigger a separate review and additional safety questions.

FDA’s OTC monograph system reduces the value of conventional drug patent blocking. It does not remove obligations relating to current good manufacturing practice, stability, quality control, labeling, adverse-event reporting, or facility compliance. (FDA, 2023b; FDA, 2024)

What is the Orange Book status of 7 Select Anti-Diarrheal?

A private-label OTC loperamide product generally does not have the same Orange Book patent-listing profile as a prescription drug approved through a full NDA. The relevant commercial protections are more likely to involve:

• Manufacturer know-how
• Contract manufacturing arrangements
• Product specifications
• Trade dress
• Packaging
• Private-label supply agreements
• Formulation patents held by a third party
• Process patents
• Regulatory exclusivity attached to a particular approved application, where applicable

Paragraph IV litigation is therefore not the expected entry mechanism for a conventional 7 Select loperamide product. A generic or private-label competitor can typically enter by producing a monograph-compliant product, subject to FDA requirements and any enforceable third-party rights.

When does loperamide lose exclusivity?

Loperamide’s core small-molecule exclusivity has expired. The active ingredient is available through multiple generic and store-brand products. There is no meaningful composition-of-matter barrier to a new compliant loperamide product.

Exclusivity category	Status for conventional loperamide
Compound patent	Expired
Basic oral tablet protection	Expired or commercially weak
Prescription-style market exclusivity	Not the primary barrier
OTC monograph access	Available subject to compliance
Formulation patents	Product-specific and potentially relevant
Manufacturing patents	Process-specific and potentially relevant
Retailer private-label rights	Contractual, not molecule-based

The commercial question is therefore whether a new product can achieve lower delivered cost, stronger consumer acceptance, better stability, or a differentiated format.

What formulation opportunities exist beyond the standard caplet?

Orally disintegrating tablets

An orally disintegrating loperamide tablet could target consumers who have difficulty swallowing during acute gastrointestinal illness. The formulation would require careful control of taste, mouthfeel, mechanical strength, and moisture sensitivity.

Potential excipient systems include:

• Mannitol for cooling mouthfeel and bulk
• Crospovidone or croscarmellose sodium for rapid disintegration
• Microcrystalline cellulose for structure
• Polyvinylpyrrolidone or specialized binders
• Flavor and sweetener systems
• Coated loperamide particles for taste masking

The main commercial risk is that an ODT may require more expensive excipients, specialized packaging, and tighter humidity control than a standard caplet.

Liquid or suspension products

A liquid loperamide product could improve dose flexibility, but it creates formulation challenges:

• Low-dose uniformity
• Solubility or suspension stability
• Preservative selection
• Flavor masking
• Measuring-device accuracy
• Pediatric misuse risk
• Labeling limitations

A liquid product marketed for young children would face significant safety and regulatory scrutiny. The commercial target would more likely be adults who cannot swallow tablets, but that segment may not justify the added manufacturing and packaging cost.

Powder or stick-pack format

A single-dose powder or granule could be positioned for travel, emergency kits, and consumers who prefer water-dispersible products. The principal excipient requirements would be flowability, moisture resistance, rapid dispersion, and taste masking.

A stick-pack format also creates packaging and line-conversion costs. Its strongest use case is convenience rather than clinical differentiation.

Fast-disintegrating coated tablet

A coated-particle tablet may provide the best balance between consumer experience and manufacturing efficiency. Loperamide particles can be taste-masked before compression, while the tablet remains an immediate-release product.

This approach may support claims relating to taste, swallowability, or rapid disintegration, but it raises process complexity and may create patent exposure if the coating technology is licensed from a specialty excipient supplier.

How strong is the patent estate for 7 Select Anti-Diarrheal?

The patent estate is likely weak at the molecule level and potentially moderate at the product-platform level.

Asset area	Estimated protection strength	Reason
Loperamide active ingredient	Low	Long-established generic active
Conventional caplet	Low	Routine dosage form and excipients
Standard dissolution profile	Low	Limited differentiation
Taste-masked dosage form	Moderate	May contain non-obvious particle or coating technology
ODT formulation	Moderate	Claims can focus on structure and performance
Novel combination product	Moderate to high	Greater technical and regulatory complexity
Manufacturing process	Moderate	Depends on narrow process claims and evidence
Packaging	Low to moderate	May protect a specific moisture or unit-dose configuration
Trade dress and retailer positioning	Commercially useful	Non-patent protection can support shelf differentiation

A freedom-to-operate review should prioritize third-party patents covering taste-masking polymers, orally disintegrating matrices, co-processing excipients, specialized lubricants, and coated active particles. Standard excipients themselves are generally commodities, but proprietary grades and processing methods may be licensed or patent-protected.

Which companies compete with 7 Select Anti-Diarrheal?

The competitive landscape includes branded, generic, and retailer-controlled products:

Competitor group	Examples	Competitive basis
Branded loperamide	Imodium and related products	Brand trust, product range, pharmacy presence
Store brands	Retailer-owned loperamide products	Price and shelf access
Generic manufacturers	Large OTC and pharmaceutical suppliers	Manufacturing scale and distribution
Alternative antidiarrheals	Bismuth subsalicylate products	Different active ingredient and consumer positioning
Gastrointestinal wellness products	Probiotic and rehydration products	Adjacent symptom-management market

7 Select’s main competitive advantages are retailer distribution, private-label pricing, and procurement leverage. Its main disadvantages are lower brand recognition and limited ability to command a premium without a differentiated format.

What licensing deals could create commercial value?

The most relevant licensing opportunities are excipient and delivery-technology agreements rather than loperamide molecule licenses.

Potential targets include:

• Taste-masking technology for bitter or unpleasant actives
• Co-processed direct-compression excipients
• Low-moisture ODT platforms
• Unit-dose stick-pack systems
• Child-resistant and senior-friendly packaging
• Stability-enhancing film coatings
• Automated dose-metering systems for liquids

A license is commercially justified only if the technology produces a measurable benefit, such as lower tablet rejection, faster compression, longer shelf life, reduced packaging cost, or a defendable consumer claim. A high-cost excipient platform with no meaningful retail price premium would weaken the private-label economics.

What generic launch scenarios exist for loperamide products?

Low-cost conventional caplet

This is the fastest and lowest-risk launch model. It relies on standard excipients, contract manufacturing, and monograph-compliant labeling. Margin depends on scale, retailer access, and procurement.

Premium private-label ODT

This model targets consumers seeking convenience. It can support higher gross margins but requires taste masking, specialized packaging, and stronger quality controls.

Travel-oriented unit dose

A blister or stick-pack format can target convenience stores, travel retailers, workplace first-aid kits, and emergency preparedness channels.

Combination gastrointestinal product

A combination product may offer differentiation but carries greater clinical, labeling, and regulatory risk. It should not be treated as a simple excipient extension of the existing caplet.

What manufacturing and IP barriers affect commercial expansion?

The principal barriers are operational rather than compound-patent based:

• Low-dose blend uniformity
• Tablet segregation during high-speed production
• Lubrication-related dissolution changes
• Moisture sensitivity of ODT and powder formats
• Taste masking without delayed release
• Packaging line compatibility
• Stability in hot and humid distribution environments
• Consistent supply of pharmaceutical-grade excipients
• Contract manufacturer capacity
• FDA inspection and quality-system performance

For the standard caplet, manufacturing scale and cost control are more important than patent ownership. For differentiated formats, process reproducibility and third-party technology rights become more important.

Key Takeaways

• 7 Select Anti-Diarrheal is a private-label loperamide hydrochloride product with limited molecule-level patent exposure.
• The standard immediate-release caplet is best optimized through direct compression, controlled lubrication, rapid disintegration, and low-cost excipients.
• The strongest commercial opportunities are ODTs, taste-masked tablets, travel-dose formats, and packaging-led differentiation.
• Conventional excipient combinations are unlikely to support strong patent protection without demonstrated technical effects.
• The principal IP review should cover taste-masking systems, ODT platforms, coated particles, manufacturing processes, and packaging technologies.
• Paragraph IV litigation and Orange Book blocking are not the primary risks for a conventional OTC loperamide launch.
• Retail distribution, procurement scale, and private-label contracting are more important to value than compound exclusivity.
• Any novel dosage form must remain consistent with FDA labeling, safety warnings, monograph conditions, and quality requirements.

FAQs

Can 7 Select Anti-Diarrheal be reformulated with different excipients?

Yes. A reformulation can replace fillers, binders, disintegrants, glidants, lubricants, or coating systems, provided the finished product remains compliant with applicable FDA quality, stability, dissolution, and labeling requirements.

Is loperamide suitable for an extended-release tablet?

An extended-release product would require a separate technical and regulatory analysis. It could alter exposure, dosing, safety, and labeling and would not be a routine excipient substitution for the existing immediate-release product.

Can an ODT loperamide product be marketed for children?

The pediatric labeling position is constrained by loperamide safety warnings and age restrictions. An ODT format does not independently establish pediatric suitability or remove the need for age-specific regulatory review.

Which excipient is most important for rapid loperamide tablet disintegration?

The superdisintegrant system is usually the principal design variable, but performance also depends on compression force, lubricant level, tablet porosity, filler selection, and moisture content.

Does a private-label loperamide product need a license from the branded manufacturer?

No molecule license is generally required for a compliant generic or private-label loperamide product. A license may be required if the formulation uses proprietary taste-masking, ODT, coating, packaging, or manufacturing technology.

References

1. U.S. Food and Drug Administration. (2023a). Loperamide hydrochloride drug facts and labeling information. FDA.

2. U.S. Food and Drug Administration. (2023b). Over-the-counter monograph M007: Antidiarrheal drug products for over-the-counter human use. FDA.

3. U.S. Food and Drug Administration. (2024). Drug products marketed under the OTC monograph order system. FDA.

4. DailyMed. (2024). Loperamide hydrochloride tablet labeling. National Library of Medicine.

5. Code of Federal Regulations. (2024). 21 C.F.R. Part 335: Antidiarrheal products for over-the-counter human use. U.S. Government Publishing Office.